Peroxisome proliferator-activated receptor-g (PPAR-g) has essential roles in adipogenesis and glucose homeostasis, and is a molecular target of insulin-sensitizing drugs [1] [2] [3] . Although the ability of PPAR-g agonists to antagonize inflammatory responses by transrepression of nuclear factor kappa B (NF-kB) target genes is linked to antidiabetic 4 and antiatherogenic actions 5 , the mechanisms remain poorly understood. Here we report the identification of a molecular pathway by which PPAR-g represses the transcriptional activation of inflammatory response genes in mouse macrophages. The initial step of this pathway involves ligand-dependent SUMOylation of the PPAR-g ligand-binding domain, which targets PPAR-g to nuclear receptor corepressor (NCoR)-histone deacetylase-3 (HDAC3) complexes on inflammatory gene promoters. This in turn prevents recruitment of the ubiquitylation/19S proteosome machinery that normally mediates the signal-dependent removal of corepressor complexes required for gene activation. As a result, NCoR complexes are not cleared from the promoter and target genes are maintained in a repressed state. This mechanism provides an explanation for how an agonist-bound nuclear receptor can be converted from an activator of transcription to a promoter-specific repressor of NF-kB target genes that regulate immunity and homeostasis.
NCoR and the related factor SMRT (silencing mediator of retinoic acid and thyroid hormone receptors) are components of corepressor complexes containing HDAC3, transducin beta-like protein-1 (TBL1) and TBLR1 that interact with a subset of unliganded nuclear receptors and mediate active transcriptional repression [6] [7] [8] [9] [10] [11] [12] . Liganddependent dismissal of these complexes requires Ubc5-dependent ubiquitylation and proteosomal degradation, with TBLR1 functioning as an essential E3 ligase 13 . Recent studies indicate that NCoR/ SMRT complexes are also required for basal repression of a subset of NF-kB and AP-1 target genes [13] [14] [15] , with loss of NCoR resulting in a partially activated phenotype in macrophages 14 . We note that a number of inflammatory response genes that are derepressed in NCoR-deficient macrophages are also subject to transrepression by PPAR-g agonists, suggesting a possible role for NCoR in this process.
We focused on the mouse inducible nitric oxide synthase gene (iNOS, also known as Nos2) as a model because it is one of several inflammatory response genes expressed by macrophages that is strongly induced by lipopolysaccharide (LPS) 16 and negatively regulated by PPAR-g agonists 17 . Inhibition of NCoR expression using an NCoR-specific short interfering (si)RNA validated for efficacy 13 ( Supplementary Fig. S1 ) resulted in complete reversal of iNOS transrepression by the synthetic PPAR-g ligands rosiglitazone and GW0072 (ref. 18) (Fig. 1a) . Consistent with these findings, knock- Figure 1 | PPAR-g prevents LPS-induced dissociation of the NCoR-HDAC3 complex from the iNOS promoter. a, Northern blot analysis indicating that siRNAs directed against NCoR abolish rosiglitazone-(Ro) and GW0072-dependent repression of LPS-induced iNOS expression. Lamin siRNA was used as a control b, Rosiglitazone and GW0072 inhibit release of NCoR from the iNOS promoter as shown by ChIP assay. The fraction of cell lysate used in the immunoprecipitation is shown (10% input). c, siRNAs directed against TBL1, TBLR1 or Ubc5c prevent LPS induction of the iNOS promoter in transiently transfected RAW264.7 macrophages. Error bars represent standard deviations of triplicate, independent determinations. Asterisks, P , 0.01 compared to LPS induction. d, Rosiglitazone prevents LPSdependent recruitment of Ubc5 to the iNOS promoter as detected by ChIP assay. e, PPAR-g binds to the Cd36 and iNOS promoters in a liganddependent manner as detected by ChIP assay. f, Knockdown of NCoR expression prevents PPAR-g recruitment to the iNOS promoter as detected by ChIP assay.
down of NCoR expression, but not SMRT expression, resulted in the reversal of repression of an iNOS promoter reporter by PPAR-g in RAW264.7 macrophages (Supplementary Fig. S2a ). Potential roles for NCoR-associated HDAC proteins were supported by the finding that treatment with 10 nM of the histone deacetylase inhibitor trichostatin A reversed rosiglitazone-dependent transrepression of iNOS ( Supplementary Fig. S2b ). To evaluate specifically the role of HDAC3, the effect of a validated HDAC3-specific pool of siRNAs ( Supplementary Fig. S1 ) was tested in RAW264.7 cells. The HDAC3-specific siRNAs, but not control siRNAs directed against HDAC7, reversed the transrepression observed on the iNOS promoter in this system ( Supplementary Fig. S2c ).
These observations predicted that NCoR-HDAC3-TBL complexes should associate with the iNOS promoter. Chromatin immunoprecipitation (ChIP) experiments confirmed that NCoR, HDAC3, TBL1 and TBLR1 were present on the iNOS promoter under basal conditions, and that the NCoR and HDAC3 components cleared following LPS stimulation (Fig. 1b) . However, in cells treated with rosiglitazone or GW0072, both NCoR and HDAC3 remained on the iNOS promoter after LPS stimulation (Fig. 1b) . Because signaldependent induction of NF-kB target genes has been suggested to require removal of NCoR complexes through Ubc5-dependent ubiquitylation 13 , we used validated siRNAs directed against TBL1, TBLR1 and the ubiquitin conjugating enzyme Ubc5c (ref. 13 , also known as Ube2d3), all of which inhibited iNOS induction in response to LPS (Fig. 1c) . These data are consistent with the hypothesis that the TBL1-TBLR1-recruited ubiquitylation complex is required for LPS-dependent clearance of NCoR and HDAC3 from the iNOS promoter, and that PPAR-g represses iNOS activation by preventing TBL1-TBLR1-dependent corepressor clearance.
We next used ChIP assays to evaluate whether an ordered sequence of events was required for NCoR clearance in response to LPS stimulation in the presence or absence of rosiglitazone. Although NCoR was cleared from the iNOS promoter within 10 min of LPS treatment, pretreatment of cells with rosiglitazone inhibited clearance at all time points tested (Fig. 1d) . Notably, Ubc5 was rapidly recruited to the iNOS promoter following LPS stimulation in the absence of rosiglitazone, but was not recruited to the promoter when rosiglitazone was present (Fig. 1d) . These results suggest that PPAR-g acts to repress LPS induction of the iNOS gene by preventing recruitment of the Ubc5/19S proteosome machinery required for the clearance of NCoR and HDAC3.
Evaluation of the iNOS promoter (negatively regulated by PPAR-g) and the Cd36 promoter (positively regulated by PPAR-g) 19 in macrophages revealed that PPAR-g was recruited to both promoters in a ligand-dependent manner (Fig. 1e) . As expected, the p65 component of NF-kB was recruited exclusively to the iNOS promoter in response to LPS, and was not affected by rosiglitazone treatment (Fig. 1e) . The recruitment of PPAR-g to the iNOS promoter did not involve sequence-specific DNA binding because a PPAR-g mutant (PPAR-g C126A/E127A ) containing amino acid substitutions in the DNA-binding domain that abolish binding to PPAR-g response elements and its recruitment to the Cd36 promoter, was efficiently recruited to the iNOS promoter ( Supplementary Fig.S3a ). This is consistent with previous studies of PPAR-g C126A/E127A indicating that it does not activate PPAR-g target genes but that it retains transrepression activity 20 . Ligand-dependent interaction of PPAR-g with the iNOS promoter was abolished by siRNA-mediated knockdown of NCoR, indicating that NCoR is required for PPAR-g recruitment (Fig. 1f) . Similar results were obtained for four additional LPSinducible, PPARg-sensitive promoters: Ccl3, Ccl7, Cxcl10 and Tgtp
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( Supplementary Fig. S3b, c) .
The observation that ligand-dependent recruitment of PPAR-g to LPS-responsive promoters requires NCoR raises a paradox, because ligand binding disrupts direct interactions between NCoR and PPAR-g 18 . To identify PPARg-interacting proteins that might potentially resolve this paradox, a yeast two-hybrid screen was performed using a library constructed from messenger RNA derived from primary mouse macrophages. One of the clones isolated in this screen encoded the first 208 amino acids of PIAS1 (protein inhibitor of activated STAT1), initially identified as a suppressor of interferondependent transcription 21 and now known to belong to a family of SUMO E3 ligases 22 . The region of PIAS1 isolated in this screen (hereafter referred to as PIAS1-N, see Supplementary Fig. S4a ) contains motifs previously shown to interact with various nuclear receptors [23] [24] [25] . The interaction between PPAR-g and the PIAS1 clone was confirmed both by yeast survival and a-galactosidase liquid assays ( Supplementary Fig. S4b ). Furthermore, co-immunoprecipitation experiments using antibodies directed against either endogenous or epitope-tagged PPAR-g and PIAS1 showed a basal interaction in RAW264.7 cells and primary macrophages that was modestly enhanced by treatment with rosiglitazone (Fig. 2a) .
SUMOylation of transcription factors has previously been correlated with impaired transcriptional activation and/or transcriptional repression [26] [27] [28] . The PIAS1-N fragment dominantly inhibited PPARg-dependent transrepression of the iNOS promoter in RAW264.7 cells (Supplementary Fig. S4c ), suggesting a role for PIAS1 or other PIAS proteins in this process. To specifically evaluate the consequences of loss of PIAS1 expression, transfection of validated PIAS1 siRNAs ( Supplementary Fig. S1 ) resulted in significant inhibition of PPARg-dependent repression of the iNOS promoter, similar to the effects observed for NCoR siRNA (Fig. 2b) , but did not impair transcriptional activation of a positively regulated PPAR-g target gene (data not shown). Moreover, siRNA-mediated knockdown of PIAS1 in primary macrophages abolished PPAR-g transrepression of the endogenous iNOS gene (Fig. 2c) . Finally, knockdown of Ubc9, the SUMOylation pathway rate-limiting E2 ligase, significantly impaired PPARg-dependent transrepression of iNOS in both RAW264.7 cells and primary macrophages (Fig. 2c and Supplementary Fig. S5a ). These results suggest that PIAS1/Ubc9-mediated PPAR-g SUMOylation is required for PPARg-dependent transrepression.
ChIP assays were next performed in macrophages to determine the roles of PIAS1 and Ubc9 in ligand-dependent recruitment of PPAR-g to the iNOS promoter and in the prevention of NCoR clearance. Knockdown of PIAS1 expression abolished recruitment of PPAR-g to the iNOS promoter, but did not affect recruitment to the positively regulated Cd36 promoter (Fig. 2d) . In addition, knockdown of PIAS1 or Ubc9 prevented the retention of NCoR on the iNOS promoter in the presence of rosiglitazone and LPS (Fig. 2e) .
SUMOylation of the PPAR-g2 AF-1 domain at residue K107 (equivalent to K77 of PPAR-g1) inhibits ligand-dependent activation of positively regulated target genes 29 . The primary amino acid sequence of murine PPAR-g shows an additional SUMOylation consensus sequence (wKXE/D; where w represents a hydrophobic amino acid and X refers to any amino acid) 30 at K365 (corresponding to K367 in the human PPAR-g sequence, Fig. 3a) . Notably, crystal structures of the apo and rosiglitazone-bound forms of PPAR-g indicate that the primary amine group of K365 is oriented towards the interior of the ligand-binding domain in the apo form, but is solvent-exposed in the rosiglitazone-bound form (Fig. 3a) . Because this amino group is the point of covalent attachment of SUMO, the PPAR-g crystal structures suggest that K365 could be SUMOylated in a ligand-dependent manner. To test this hypothesis, K365 of PPAR-g was mutated to arginine (K365R), and the wild-type and mutant proteins were tested for SUMOylation in vivo and in vitro. Wild-type PPAR-g, but not PPAR-g K365R , showed a significant increase in SUMOylation following treatment with rosiglitazone ( Fig. 3b and data not shown)
To determine the functional consequences of K77-and K365-dependent SUMOylation, the ability of each mutant to inhibit the iNOS promoter and/or transactivate a positively regulated PPARgdependent promoter was tested in RAW264.7 cells. PPAR-g K365R did not inhibit the iNOS promoter, whereas PPAR-g K77R retained full transrepression activity (Fig. 3c) . PPAR-g K77R showed enhanced transactivation function, consistent with previous findings 29 , whereas PPAR-g K365R showed approximately the same activity as wild-type PPAR-g on the positively regulated Aox-TK luciferase promoter (Fig. 3d) . ChIP assays indicated that wild-type PPAR-g and PPAR-g K77R were efficiently recruited to the iNOS promoter in response to rosiglitazone, whereas PPAR-g K365R was not (Fig. 3e) . In contrast, wild-type PPAR-g and each of the PPAR-g mutants were recruited to the positively regulated Cd36 promoter (Fig. 3f) .
Mammalian two-hybrid assays were used to explore effects of SUMOylation on interactions of PPAR-g with NCoR and HDAC3. Previous studies have demonstrated that unliganded PPAR-g binds to one of two nuclear receptor interaction domains in the extreme C terminus of NCoR (termed the IDC), and that this interaction is reversed by ligand 18 . Mammalian two-hybrid assays confirmed this interaction and demonstrated that knocking down expression of PIAS1 or Ubc9 did not influence ligand-dependent dissociation of PPAR-g from the IDC (Fig. 4a) . In contrast, PPAR-g showed a ligand-dependent increase in interaction with an NCoR deletion mutant lacking the IDC that was abolished by knocking down Ubc9 or PIAS1 (Fig. 4a and Supplementary Fig. S5b ). Mammalian twohybrid assays also showed an interaction between PPAR-g and HDAC3, but this interaction was only modestly affected by ligand or by knockdown of PIAS1 or Ubc9 (Supplementary Fig. S5c ). Consistent with these results, knockdown of HDAC3 reduced, but did not prevent, recruitment of PPAR-g to the iNOS promoter in response to ligand, as determined by ChIP assays (Fig. 4b) . These results suggest that NCoR is required for ligand-dependent recruitment of SUMOylated PPAR-g to the iNOS promoter and that HDAC3 plays a quantitative role in stabilizing this interaction.
The present studies define sequential steps of a pathway mediating ligand-dependent transrepression of inflammatory response genes by PPAR-g in macrophages (Fig. 4c) . Genes subject to transrepression by this pathway are marked in the basal state by the presence of NCoR-HDAC3-TBL corepressor complexes. LPS signalling results in the clearance of the NCoR and HDAC3 components of this complex in a TBL1-, TBLR1-and Ubc5-dependent manner, allowing a switch from active repression to transcriptional activation. The PPARg-dependent transrepression pathway is initiated by ligand-induced SUMOylation Bottom panels, close-up views of this region of the apo PPAR-g LBD surface, with the arrow pointing to a hydrogen atom in the K365 side chain (left), and rosiglitazone-bound PPAR-g LBD (right), with the arrow pointing to solvent-exposure of the nitrogen atom of the primary amine of K365 (shown in blue). b, SUMOylation of PPAR-g at K365 occurs in a ligand-dependent manner. WT, wild type; NT, non-transfected cells; SuPPAR-g, SUMOylated PPAR-g species. HA-tagged WT or K365R PPAR-g was immunoprecipitated from cell lysates and immunoblotted for HA-tag or SUMO Myc-tag. c, d, SUMOylation of PPAR-g at K365 but not K77 is required for transrepression of the iNOS promoter (c), but not transactivation of the AoxTK promoter (d), in transfected RAW264.7 macrophages. Error bars represent standard deviations of triplicate, independent determinations. e, f, SUMOylation of PPAR-g at K365 is required for recruitment to the iNOS promoter (e) but not the Cd36 promoter (f) in RAW264.7 cells, as demonstrated by ChIP assays.
of the ligand-binding domain. This modification targets PPAR-g to NCoR complexes associated with the promoter, preventing Ubc5 recruitment in response to LPS signals. As a result, NCoR complexes are not cleared from the promoter and target genes are maintained in a repressed state. Interestingly, allosteric changes in the PPAR-g ligand-binding domain required for entry into the SUMOylationdependent transrepression pathway are distinct from changes that regulate interactions with conventional coregulators. It will be of interest to define the extent to which this pathway is used by PPAR-g and other nuclear receptors, and to explore how this mechanism can be exploited to develop new drugs for the treatment of inflammatory and metabolic diseases.
METHODS
Plasmids and cell culture. Primary macrophages were elicited by intraperitoneal injection with 2 ml of thioglycollate. HA-tagged wild-type and K77R and K365R PPAR-g mutants were cloned into a pcDNA3 backbone (Invitrogen). Wild-type (WT)-PIAS1 and PIAS1-N were cloned into a 2 £ FLAG-pcDNA3 expression vector. PPAR-g bait used for the yeast two-hybrid, including the DNA-binding domain, hinge region and ligand-binding domain (PPAR-g DHL), was inserted into the pGBK7 vector (Clontech). For RNAi experiments, smart-pool siRNAs (Dharmacon) against PIAS1, Ubc9, HDAC3, HDAC7 or control non-specific and (previously validated) NCoR were transfected into primary macrophages using lipofectamine 2000 (Invitrogen) and incubated for 48 h. Effects of these siRNAs on cellular protein levels are illustrated in Supplementary Fig. S1 . Yeast two-hybrid screen. A yeast two-hybrid library was generated with the pGAD vector (Clontech) with RNA derived from primary peritoneal macrophages elicited from normal and hypercholesterolaemic mice. The library was transformed into the AH109 yeast strain and was mated to Y187 strain transformed with PPAR-g DHL bait. Colonies were picked 4-6 days after mating. Polymerase chain reaction (PCR) inserts were amplified and sequenced. Yeast plasmids were purified from individual clones. Finally, interactions were verified by a-galactosidase activity in yeast liquid culture assays. Transient transfection. The RAW264.7 mouse macrophage cell line was transiently transfected with iNOS or Aox-TK promoters directing luciferase expression, as previously described 17 . For transrepression experiments, wildtype PPAR-g or PPAR-g mutants were transfected at a 3:1 (PPAR-g to reporter plasmid) ratio using Superfect reagent (Qiagen). For siRNA experiments, RAW264.7 cells were transfected with siRNAs (40 nM) using Superfect reagent for 48 h before activation with PPAR-g ligands and LPS induction (6 h). In all transfections, cells were treated with 0.1 mM rosiglitazone, stimulated with 1 mg ml 21 LPS and assayed for luciferase activity 6 h later. For mammalian two-hybrid assays, 200 ng of UAS-TK luciferase reporter and 100 ng each of VP16-PPAR-g wild-type and Gal-DBD-NCoR constructs were transfected into RAW264.7 cells. VP16 refers to the transactivation domain of herpes simplex viral protein 16, and Gal-DBD refers to yeast Gal4 DNA-binding domain. Cells were cultured in 0.01 mM trichostatin A (TSA) before ligand treatment for 16 h. Transfection experiments evaluated each experimental condition in triplicate and results are expressed as mean^s.d. Statistical analysis was performed using Student's t-test, with P , 0.01 considered statistically significant. Chromatin immunoprecipitation assays. ChIP assays were performed as previously described 13, 14 . For each experimental condition, 2-4 £ 10 6 primary macrophages or RAW 264.7 cells were used. Cells were pre-treated with 0.1 mM rosiglitazone (1 h) and stimulated with 1 mg ml 21 LPS (1 h) before crosslinking for 10 min with 1% formaldehyde. Anti-PPAR-g antibodies H-100 (Santa Cruz) and 39338 (Active Motif) were used in combination. Antibodies against TBL1 and TBLR1 have been described previously 13, 14 . Anti-HA protein A sepharose beads (Covance) were used for wild-type and mutant HA-tagged PPAR-g proteins. Anti-HDAC3 and anti-p65 antibodies were from Santa Cruz. AntiNCoR antibody was from Affinity Bioreagents. A 150-bp region of the iNOS promoter was amplified spanning the most proximal NF-kB site to the start of transcription 16 . A 150-bp region of the mouse Cd36 promoter was amplified spanning the PPRE sequence 19 . RNA isolation, semiquantitative PCR and northern blot analysis. Total RNA (isolated by the Trizol method) was prepared from primary macrophages pretreated with 1 mM rosiglitazone (2 h) before 1 mg ml 21 LPS stimulation (6 h). One microgram of total RNA was used for cDNA synthesis, and 2 ml of cDNA was used for PCR using iNOS or inflammatory-gene-specific primers. For northern blot analysis, 10 mg total RNA and an iNOS-specific probe were used. Co-immunoprecipitations and western blotting. For co-immunoprecipitations, RAW264.7 cells or 293 cells were transfected with HA-PPAR-g (wild type) and 2 £ FLAG-PIAS1 (wild type) using Superfect reagent in 10-cm dishes. Whole-cell extracts were prepared using lysis buffer: 10 mM Tris-HCl pH 8, 420 mM NaCl, 1 mM EDTA and 0.5% NP-40 with protease inhibitor cocktail (Roche Biochem). Immunoprecipitates were washed four times with wash buffer containing 10 mM Tris-HCl pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40 and 0.5% Triton X-100, boiled in 1 £ sample loading buffer and separated by 10% SDS-PAGE. M2 anti-flag antibody (Sigma) was used at 1:1,000 dilution. Anti-HA antibody (Covance) was used at 1:1,000 dilution. Antibodies used for endogenous immunoprecipitation and western blot for PPAR-g/PIAS1 interaction experiments were obtained from Active Motifs and Santa Cruz, respectively. SUMOylation assays. For in vivo SUMOylation experiments, 250 mg total protein extract was prepared from HeLa cells transfected with HA-tagged wild-type PPAR-g or SUMO point mutants (K77R and K365R) and Myc-tagged SUMO-1. Cell lysates were immunoprecipitated and washed four times in lysis buffer containing 0.1% SDS, 0.5% deoxycholate, 0.5% TritonX-100, 1 mM EDTA, 20 mM Tris-HCl pH 7.8 and 150 mM NaCl. Immunoprecipitates were resolved by SDS-PAGE and immunoblotted using anti-HA or anti-Myc antibodies. 
